Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
- Francis J. Giles
- , Delphine Rea
- , Gianantonio Rosti
- , Nicholas C.P. Cross
- , Juan Luis Steegmann
- , Laimonas Griskevicius
- , Philipp le Coutre
- , Daniel Coriu
- , Ljubomir Petrov
- , Gert J. Ossenkoppele
- , Francois Xavier Mahon
- , Susanne Saussele
- , Andrzej Hellmann
- , Perttu Koskenvesa
- , Tim H. Brümmendorf
- , Gunther Gastl
- , Fausto Castagnetti
- , Beatrice Vincenzi
- , Jens Haenig
- , Andreas Hochhaus
- Northwestern University Feinberg School of Medicine
- Hopital Saint-Louis
- University of Bologna
- University of Southampton, Faculty of Medicine
- Hospital de la Princesa
- Vilnius University
- Charité – Universitätsmedizin Berlin
- Carol Davila University of Medicine and Pharmacy
- Ion Chiricuta Instititute of Oncology
- VU University Medical Center
- University Bordeaux-Segalen
- Central Institute of Mental Health, Medical Faculty Mannheim, University Heidelberg
- Medical University of Gdańsk
- Helsinki University Central Hospital
- University Hospital Aachen
- Medical University Innsbruck
- Novartis Oncology Italy
- Novartis Pharma GmbH
- Jena University Hospital
Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
29
Citations
(Scopus)